Proactive - Interviews for investors

Proactive
  • 4.5 (2)
  • Investing
  • Updated Daily

Welcome to the Proactive podcast channel – the destination for breaking news on growth companies and up to the minute market coverage. Here we plug you into what’s new and exciting in the world of business.

  1. 21h ago

    Purepoint expands Nova Uranium discovery with new high-grade results at Dorado

    Purepoint Uranium Group CEO Chris Frostad joined Steve Darling from Proactive reported encouraging new assay results from its 2026 winter drill program at the Nova Target, part of the 50/50 Dorado Joint Venture with IsoEnergy Ltd., further strengthening the project's potential as a significant uranium discovery in Saskatchewan's Athabasca Basin. Frostad shared with Proactive the latest results, highlighting that Hole NV26-05 returned 1.65% U₃O₈ over 0.3 metres from a depth of 390.4 metres at the unconformity. The intercept adds to a growing body of evidence supporting the presence of uranium mineralization along the Nova electromagnetic (EM) conductor. The nine-hole winter drilling campaign successfully intersected uranium mineralization in multiple holes while also providing valuable geological and structural information that will help guide future exploration efforts. According to Frostad, the results have significantly enhanced the company's understanding of the mineralized system and improved its ability to identify and prioritize future drill targets. Purepoint said the program was designed not only to test the geological and structural controls associated with uranium mineralization but also to refine the geometry of the Nova conductor. The drilling generated important data that has allowed geologists to better define the orientation and characteristics of the mineralized zones. Management noted that the additional uranium intercepts, combined with improved geological and geophysical interpretation, are helping to narrow in on the most prospective areas for follow-up drilling. The company believes its growing understanding of the relationship between geologic structures and geophysical responses is leading to increasingly precise drill targeting as exploration advances. The winter campaign marks another important step in evaluating the Nova system, which continues to demonstrate characteristics associated with high-grade Athabasca Basin uranium deposits. The project remains a key focus within the Dorado Joint Venture as Purepoint and IsoEnergy continue to unlock the potential of the property. Frostad also confirmed that the 2026 summer drill program has now been completed. Results from that campaign are currently being compiled and analyzed, with assay results and interpretations expected to be reported in the near future. #proactiveinvestors #purepointuraniumgroup #tsxv #ptu #otcqb #ptuuf #Uranium #IsoEnergy #Uranium #AthabascaBasin #UraniumExploration #NuclearEnergy #EnergyTransition #Mining #ResourceSector #Exploration #CriticalMinerals #U3O8 #JuniorMining #MiningStocks #CleanEnergy #CanadaMining #Investing #Stocks #ProactiveInvestors #UraniumNews

  2. 21h ago

    Medicus Pharma secures Pfizer ADC deal, advances SkinJect and precision oncology strategy

    Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to discuss a transformative agreement with Pfizer that significantly strengthens the company’s position in precision oncology and provides key resources to advance its lead cancer program. Under the development and licensing agreement, Medicus has secured rights to a CD228-targeted antibody-drug conjugate (ADC) program, while Pfizer is contributing approximately $2 million in development funding, along with inventory and infrastructure support. Bokhari described the transaction as a major milestone that effectively provides the company with the resources needed to continue development from where Pfizer concluded its Phase 1 dose-escalation work. The CD228-targeted ADC is being developed for the treatment of solid tumors, including refractory melanoma, and now represents the centerpiece of Medicus’ evolving oncology strategy. Bokhari said the agreement allows the company to move forward with a capital-efficient approach while leveraging the extensive scientific and clinical groundwork already completed by Pfizer. Beyond oncology, Medicus continues to make progress with its SkinJect program, which is focused on the treatment of basal cell carcinoma and related conditions. Bokhari noted that final clinical trial results recently published on ClinicalTrials.gov identified the 200-microgram patch as the optimal dose for future registrational studies. The company is now concentrating its efforts on advancing SkinJect in patients with Gorlin syndrome, a rare genetic condition that can lead to the development of multiple basal cell carcinomas throughout a patient’s lifetime. Medicus is preparing to move forward with the FDA-approved pivotal SkinJect 005 study while simultaneously recruiting patients for the trial. At the same time, Bokhari said the company is positioning the broader nodular basal cell carcinoma opportunity for potential out-licensing, allowing Medicus to focus internal resources on the areas where it sees the strongest risk-adjusted return. To support the commercial potential of SkinJect, Medicus commissioned an independent reimbursement analysis that suggests the treatment could potentially achieve reimbursement levels of $25,000 or more per patient. Bokhari noted that the rare disease and potential pediatric disease characteristics associated with Gorlin syndrome could provide attractive regulatory and commercial advantages. He described SkinJect as “partner-ready” and indicated that the company is actively exploring opportunities to unlock additional value through strategic partnerships. Bokhari characterized the Pfizer agreement as a paradigm shift for Medicus, transforming the company into a precision oncology-focused biotechnology business while maintaining a disciplined approach to capital allocation. He compared the strategy to a Berkshire Hathaway-style model for drug development, where resources are selectively deployed into programs with the highest potential returns. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #SkinJect #Pfizer #PrecisionOncology #Biotech #CancerResearch #ADC #Melanoma #DrugDevelopment #ClinicalTrials #SkinJect #GorlinSyndrome #Biotechnology #HealthcareInnovation #Oncology #LifeSciences

  3. 1d ago

    Ocean Power Technologies demonstrates WAM-V maritime drone in U.S. Army coastal trials

    Ocean Power Technologies CEO Philipp Stratmann joined Steve Darling from Proactive to discuss the company's participation in a week-long U.S. Army demonstration designed to evaluate advanced autonomous maritime technologies operating in some of the most challenging nearshore environments. The demonstration is being conducted by the U.S. Army Engineer Research and Development Center's (ERDC) Coastal and Hydraulics Laboratory at its Field Research Facility in Duck, North Carolina. Following a competitive technical evaluation process, OPT was selected to showcase its WAM-V® autonomous maritime drone platform in live coastal conditions that include surf zones, breaking waves, strong currents and coastal inlets. The program is focused on identifying technologies capable of sustaining uncrewed surface vehicle operations in environments that are traditionally difficult and potentially hazardous for manned vessels. During the trials, ERDC is evaluating platforms and sensing technologies that can support critical missions such as bathymetric mapping and submerged-hazard detection. These capabilities have important applications for both military and civilian operations. Potential uses include U.S. Army Corps of Engineers civil infrastructure projects as well as military logistics-over-the-shore missions, where accurate information about water depths, underwater obstacles and shoreline conditions is essential for safe navigation and operational planning. OPT's WAM-V platform is specifically engineered for harsh marine environments. Its unique articulating suspension system helps improve stability while reducing structural stress when operating in waves and rough water conditions. The vessel's modular design also allows it to carry a variety of sensing and data-collection payloads, making it suitable for defense, scientific research, environmental monitoring and civil engineering applications. While participation in the demonstration does not constitute a procurement contract or guarantee future business, ERDC has indicated that technologies demonstrating strong performance could be considered for additional testing and evaluation programs, subject to future funding availability. #proactiveinvestors #oceanpowertechnologiesinc #nyseamerican #optt #PhillipStratmann #PowerBuoy #WAMV #MaritimeTech #MaritimeTechnology #DefenseTech #ArtificialIntelligence #AutonomousSystems #USCoastGuard #OceanInnovation #Defense #CleanTech

  4. 1d ago

    Itaconix sets out path to $30 million dollar revenues after record first half

    Itaconix CEO John Shaw joined Steve Darling from Proactive to discuss the company's strong first-half performance, highlighted by breakeven adjusted EBITDA, a stronger cash position, and continued revenue growth as demand for its sustainable polymer technologies expands across key markets. Shaw said the company's progress can be measured by three critical metrics moving in the right direction simultaneously: revenue growth, profitability, and cash generation. Achieving breakeven adjusted EBITDA marks an important milestone for Itaconix as it continues to scale its business while maintaining financial discipline. A major driver of growth remains the company's TSI polymer technology, which is increasingly being adopted by manufacturers of automatic dishwasher detergents across Europe and North America. Shaw noted that the addressable market remains enormous, estimating there are approximately 70 billion automatic dishwasher cycles annually across Europe and the broader EMEA region. Despite this opportunity, Itaconix products currently participate in less than 4% of that market, leaving substantial room for expansion. To accelerate adoption, the company continues to promote its SPARX formulated solutions and consumer-focused initiatives which helps customers reformulate products using more sustainable, plant-based ingredients while maintaining performance. Looking ahead, Shaw reiterated the company's goal of reaching US$30 million in annual revenue. He explained that much of the momentum needed to achieve that target is already embedded within the existing customer base, which generated the majority of first-half growth. To reach the next level, Itaconix is targeting additional large contract manufacturing partnerships across EMEA while continuing to add purpose-driven consumer brands throughout North America. Beyond detergents, Shaw outlined a much broader growth vision for the company. He said Itaconix is working with a major participant in the global paint industry to develop plant-based alternatives for specialty paint applications, targeting a segment of the approximately US$40 billion acrylic paint market. The company is also expanding into agricultural applications. Shaw revealed that Itaconix technologies are currently being evaluated in field trials covering more than 100 acres of corn and soybean crops across multiple U.S. states. Results from those trials are expected later this year or early next year. If successful, the next phase could involve testing across more than 10,000 acres, opening another potentially significant growth market. With growing adoption in detergents, emerging opportunities in paints and agriculture, and improving financial performance, Itaconix believes it is building a diversified platform capable of supporting its longer-term ambition of becoming a US$100 million revenue company. #proactiveinvestors #itaconixplc #aim #itx #otcqb #itxxf #GreenChemistry #SustainableMaterials #CleanTech #DishwasherDetergent #IndustrialInnovation #AgricultureTechnology #SpecialtyChemicals #SmallCapStocks #ResourceInvesting

  5. 1d ago

    Krakatoa Resources: Zopkhito drilling extends gold-antimony potential

    Krakatoa Resources Ltd CEO Mark Major talked with Proactive about high-grade gold and antimony results from the company’s 2026 drilling program at the Zopkhito Antimony-Gold Project and the work underway to advance the project toward a JORC-compliant resource. Major said the latest results broadly reaffirmed the grades seen in the project’s historical data. He noted that previous work had returned gold grades of around 28 grams per tonne, while the latest sample batch included grades of around 17 grams per tonne gold. On the antimony side, Major highlighted a result of around 15%, alongside grades of more than 20% encountered in previous drilling. Work is continuing across the project, including additional sampling and assessment inside the adits. Surface drilling has also moved to the western side of the project, where the company is testing a series of veins that have not previously been drilled. Looking ahead, Major said Krakatoa Resources plans to take bulk samples for metallurgical test work and carry out further geotechnical work within the adits. The company is also considering preparations for underground drilling in the next field season as it seeks to expand the resource and improve its classification. Visit Proactive’s YouTube channel for more interviews and market updates. If you found this video useful, give it a like, subscribe to the channel and enable notifications so you don’t miss future content.

  6. 1d ago

    Titan Minerals extends gold-silver mineralisation at Dynasty

    Titan Minerals CEO Melanie Leighton talked with Proactive about the latest drilling results from the company’s Dynasty Gold Project in southern Ecuador, where extensional and infill drilling continues to expand and upgrade the known gold-silver mineralisation. Leighton highlighted a new result of 16 metres at 2.8 grams per tonne gold and 9.1 grams per tonne silver, which delivered an additional 30-metre step-out on one lode. She explained that the latest announcement also included a number of infill results, with broad mineralised zones in the range of around 15 to 20 metres and grades of up to approximately 2.6 to 2.8 grams per tonne gold. According to Leighton, the drilling is contributing both additional mineralisation outside the current resource and greater confidence within existing resource areas. The latest results follow another intercept reported the previous week of just over 33 metres at 6.6 grams per tonne gold and 55 grams per tonne silver, which Leighton said also sits outside the current resource. Titan Minerals is expanding its extensional and infill drilling campaign to around 30,000 metres, with work expected to continue through the end of the year and potentially into January. The company is targeting an updated resource in the first quarter of next year, with the expanded and upgraded resource expected to feed into the Dynasty Gold Project scoping study, which is also targeted for Q1. Four diamond rigs are currently operating at the project, with an RC rig due to be added in October to test new extensions and more exploratory areas before potential follow-up diamond drilling. Visit Proactive’s YouTube channel for more interviews and market updates. Don’t forget to like the video, subscribe to the channel and enable notifications for future content.

  7. 1d ago

    Gaming Realms CEO: Content growth accelerating as company expands into new markets

    Gaming Realms PLC (LSE:GMR, OTCQX:PSDMF, FRA:RNE1) CEO Mark Segal spoke with Proactive's Stephen Gunnion about first-half performance, accelerating content licensing growth, expansion into new regulated markets and plans to increase the pace of game releases. Segal said core content licensing revenue grew 12% in the first half, followed by 23% growth in the subsequent two months, driven by content quality, market expansion, closer partner relationships and strong player engagement. On the UK, Segal noted the remote gaming duty increase began at the start of Q2 and is expected to have a greater impact in the second half, though play and gross revenue have continued to rise. "I think we may not see quite the same growth moving forward, albeit we are releasing more content now," he said. Gaming Realms is now live in 34 regulated markets, with Alberta and Argentina added since the period ended. Segal highlighted the US and Canada as the company's biggest growth markets, with further US market openings offering additional opportunities, alongside expansion into Peru, Buenos Aires province and African markets. Increased investment in content is beginning to translate into a more consistent release schedule across Slingo and Lucky Lunar, with Segal hoping for "a much more consistent level of volume coming through" to drive greater revenue engagement and more tailored games for operators and individual markets. Visit Proactive’s YouTube channel for more interviews and videos. Don’t forget to like this video, subscribe to the channel and enable notifications for future content. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy #GamingRealms #Slingo #LuckyLuna #OnlineGaming #iGaming #GamingIndustry #GamingStocks #ContentLicensing #USGaming #CanadaGaming #LatinAmerica #InvestorNews #GamingInvestment #ProactiveInvestors #MarkSegal

  8. 1d ago

    genedrive CEO: NHS adoption and global expansion drive point-of-care testing push

    genedrive PLC (AIM:GDR) CEO Dr Gino Miele spoke with Proactive's Stephen Gunnion about the diagnostic company's progress in rapid point-of-care genetic testing, growing NHS adoption and international expansion plans. Miele explained that Manchester-based genedrive has developed two CE-IVD-approved, NICE-recommended tests to help clinicians make safer prescribing decisions in emergency and acute care. The MT-RNR1 test identifies newborns at risk of irreversible hearing loss from aminoglycoside antibiotics, while the CYP2C19 test identifies stroke patients unlikely to respond well to the antiplatelet drug clopidogrel. On MT-RNR1, Miele highlighted completion of patient recruitment for the PALOH UK programme, covering more than 6,000 babies across 14 hospitals in all four UK nations, with clinical analysis under way and publication expected next month ahead of further NICE guidance in July 2027. "This will be a really important commercial catalyst for the business, alongside NHS England procurement routes as well," he said. He discussed international ambitions, including a memorandum of understanding with Saudi Arabia's Ministry of Health, routine clinical use at the National Guard hospital there, implementation at Erasmus MC in the Netherlands, and plans around FDA routes in the US. Miele also highlighted genedrive's collaboration with Thermo Fisher to develop a laboratory-format version of the CYP2C19 test, complementing its existing point-of-care offering. Longer term, genedrive is targeting further international expansion, additional clinical indications, and recurring consumables revenue as its tests become embedded in routine care pathways. Visit Proactive's YouTube channel for more interviews and market updates. Give the video a like, subscribe to the channel and enable notifications so you don't miss future content. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy #genedrive #GDR #GeneticTesting #Pharmacogenetics #Diagnostics #PointOfCareTesting #NHS #NICE #MTRNR1 #CYP2C19 #Stroke #Healthcare #MedTech #MolecularDiagnostics #PersonalisedMedicine #ThermoFisher #Investing #Proactive

See All (601)

Ratings & Reviews

4.5
out of 5
2 Ratings

About

Welcome to the Proactive podcast channel – the destination for breaking news on growth companies and up to the minute market coverage. Here we plug you into what’s new and exciting in the world of business.

Information

You Might Also Like